Exploring Three High Growth Tech Stocks in the United States

In This Article:

Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves assessing their potential for innovation and scalability within a dynamic economic landscape.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.86%

27.98%

★★★★★★

Sarepta Therapeutics

23.67%

44.28%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Ardelyx

27.19%

66.44%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Amicus Therapeutics

20.32%

62.45%

★★★★★★

AsiaFIN Holdings

60.53%

81.55%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

Travere Therapeutics

27.16%

69.88%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 253 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Neurocrine Biosciences

Simply Wall St Growth Rating: ★★★★★☆

Overview: Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally with a market cap of approximately $11.27 billion.

Operations: Neurocrine Biosciences generates revenue primarily from the research, development, and commercialization of pharmaceuticals, amounting to $2.12 billion. The company focuses on addressing neurological, neuroendocrine, and neuropsychiatric disorders across various markets.

Neurocrine Biosciences has demonstrated a robust trajectory in high-growth tech through significant R&D investment and strategic product development. In 2024, the company allocated 14.2% of its revenue towards R&D, underscoring its commitment to innovation, particularly in treatments for neurological disorders. This focus is reflected in their recent announcement of positive interim results from their KINECT-HD2 study, enhancing Neurocrine's profile in the biotech industry. Moreover, with an expected annual earnings growth rate of 29.4%, Neurocrine not only outpaces the broader US market but also solidifies its position by addressing unmet medical needs through advanced therapeutic solutions.

NasdaqGS:NBIX Earnings and Revenue Growth as at Oct 2024
NasdaqGS:NBIX Earnings and Revenue Growth as at Oct 2024

Cars.com

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Cars.com Inc. is an audience-driven technology company offering solutions for the automotive industry in the United States, with a market cap of approximately $1.03 billion.